ProTom’s accelerated focus on the MGH project comes after successfully completing its restructuring and recapitalization as offered through the Chapter 11 process, and throughout the reorganization MGH has sustained its full support to ProTom for successful project completion. The new MGH proton facility is expected to be completed and could begin treating patients in 2017.

"With unprecedented financial strength, new owners and corporate governance, ProTom is better positioned to deliver this advanced, affordable and adaptable proton therapy technology to more hospitals and physician practices," said Stephen Spotts, ProTom’s Chief Executive Officer. "Our new capital structure will better support ProTom’s continued investment in delivering innovative proton therapy solutions, and will provide a stronger foundation to execute on our strategic plans. We are no longer a startup company, and with our new financial sponsors we have truly turned international in our focus. Our new owners intend to bring this technology to an international market truly poised to take advantage of this highly sought-after proton therapy solution. Due to our reorganization, we will now have the resources we need. Nothing has changed in regard to our 510(k)–cleared equipment; what has changed is bringing in-house our own designs such as our new hand pendant, beam transport system, beam delivery system, and several mission-critical software modules. Our new power supply ensures that systems we install will be ready for proton tomography, and we expect many of our future customers will be interested in the newly interfaced cone-beam CT and patient positioning system.”


Mr. Spotts continued, “We are very confident going into this project since it is not our first. During our alpha project, while we readily achieved proton beam within 30 days of accelerator installation, generated scanning beam at gantry isocenter 12 months later, and achieved FDA clearance 15 months later, we were challenged with some mechanical issues on Radiance 330’s revolutionary compact gantry; ironing-out these issues benefitted us – resulting in design modifications that have already been incorporated into this and future projects. New procedures and algorithms have been successfully implemented for streamlining beam optics commissioning. This will dramatically facilitate and expedite the technical commissioning required on each of our future projects. We have also been performing mock treatments, validating our system’s workflow efficiency and throughput, a critical need for all our future customers. ProTom is a company devoted to proton therapy as its sole mission; this is all we do. We thank our customers, partners, and suppliers for their confidence and support throughout this process, and in particular we thank our employees for their focus and dedication to this mission.”

More HCB News